Remedy Taking a hit why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: INVESTOR who wrote (229)	4/23/1997 9:40:00 AM
From: Peter Caradonna	of 763

From WSJ....... REMEDY The Mountain View company, which focuses on internal help-desk software, has a big fan in analyst Ed Bierdeman of San Francisco-based Dakin Securities. "They're the pick of the litter, in my eye, based on their management," says Mr. Bierdeman, who recently upgraded Remedy to a "strong buy." The company pleased Wall Street the day after the Clarify bombshell by beating analysts' consensus first-quarter earnings estimate of 13 cents a share by three cents. The stock is trading around $27, less than half its 52-week high of $55.75 set last December. And over the next 12 months, Mr. Bierdeman sees the stock bouncing back to between $50 and $55.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next